Provided by Tiger Trade Technology Pte. Ltd.

HCW Biologics Inc.

2.18
+0.06002.83%
Post-market: 2.220.0400+1.83%19:34 EDT
Volume:55.70K
Turnover:120.08K
Market Cap:4.00M
PE:-0.08
High:2.23
Open:2.16
Low:2.05
Close:2.12
52wk High:44.10
52wk Low:1.50
Shares:1.84M
Float Shares:1.65M
Volume Ratio:0.17
T/O Rate:3.38%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-27.1846
EPS(LYR):-63.7804
ROE:-151.36%
ROA:-18.37%
PB:0.54
PE(LYR):-0.03

Loading ...

HCW Biologics files to sell 1.24M shares of common stock for holders

TIPRANKS
·
Aug 21

Cancer Immunotherapy Developer CEL-SCI's Q3 Net Loss Unchanged

Reuters
·
Aug 17

Inflammation Drug Developer HCW Biologics' Q2 Net Loss Widens

Reuters
·
Aug 15

HCW Biologics Q2 EPS $(11.58), Sales $135.568K Up From $6.550K YoY

Benzinga Earnings
·
Aug 15

HCW Biologics Q2 FY26 Net Loss Widens to $5.2 Million; Revenue Rises to $135,568

Reuters
·
Aug 15

HCW Biologics Reports Second Quarter 2026 Business and Clinical Development Highlights and Financial Results

THOMSON REUTERS
·
Aug 15

HCW Biologics Restates Q1 EPS, Cutting Net Income Attributable to Common Shareholders by USD 728,000

Reuters
·
Aug 15

HCW Biologics Says Q1 2026 Financial Statements Should No Longer Be Relied Upon; Error In Two-Class Method For EPS Calculation Identified; Errors Constitute Material Misstatement Of EPS; EPS Of $2.19 Per Share Overstated By $0.80 Per Share For Q1 2026; Material Weakness In Technical Accounting Review Control Identified

Benzinga Earnings
·
Aug 15

HCW Biologics - Q1 2026 Financial Statements Should no Longer be Relied upon - SEC Filing

THOMSON REUTERS
·
Aug 15

HCW Biologics - Errors Constitute Material Misstatement of EPS - SEC Filing

THOMSON REUTERS
·
Aug 15

HCW Biologics - Error in Two-Class Method for EPS Calculation Identified - SEC Filing

THOMSON REUTERS
·
Aug 15

HCW Biologics - EPS of $2.19 Per Share Overstated by $0.80 Per Share for Q1 2026 - SEC Filing

THOMSON REUTERS
·
Aug 15

HCW Biologics Says Q1 2026 Financials Cannot be Relied on Due to EPS Misstatement

Reuters
·
Aug 15

Top Brass Makes Bold Move on HCW Biologics Shares

TIPRANKS
·
Aug 01

HCW Biologics Director Scott T. Garrett Acquires 7,736 Common Shares for $19,995.56

Reuters
·
Aug 01

HCW Biologics Issues 400,000 Pre-funded Warrants in $1.6 Million Private Placement

Reuters
·
Jul 29

HCW Biologics Inc. Announces Pricing of $1.6 Million Private Placement Offering

THOMSON REUTERS
·
Jul 29

HCW Biologics Seeks FDA Pre-ind Meeting for Hcw11-018b T-cell Engager Program

Reuters
·
Jul 23

HCW Biologics - Requests Type B Pre-ind Meeting with FDA for Hcw11-018b

THOMSON REUTERS
·
Jul 23

HCW Biologics Reaches Milestones for Its Proprietary Tetravalent Second-generation T-cell Engager Program on Track to Initiate Clinical Trials in First Half 2027

THOMSON REUTERS
·
Jul 23